Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD1775
AZD 1775 · 1 trial · 1 indication
The AZD1775 dose is considered safe and tolerable if ≤ 1 of 6 patients experiences a DLT.
| Arm | Type | Description |
|---|---|---|
| AZD1775 | EXPERIMENTAL | Single-arm study. AZD1775 will be administered for 3 consecutive days at the start of week 1 and week 2 of each 21-day cycle. This study will be conducted in two parts, designated Part A and Part B. Part A is a safety lead-in. Part B will commence after the safety lead-in and will investigate the safety and efficacy of AZD1775 monotherapy in expansion cohorts of specific tumour types. |
| Name | Type | Description |
|---|---|---|
| AZD 1775 | DRUG | AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle. AZD1775 should be taken approximately 2 hours before or 2 hours after food. |
Inclusion Criteria: 1. Age ≥18 2. Previous chemotherapy for recurrent or metastatic disease. 3. Measurable disease is required for Part B expansion cohorts according to RECIST v1.1 criteria. 4. Radiation therapy completed at least 7 days prior to start of study treatment and patients must have reco...
AZD 1775 is an investigational small molecule being studied for the treatment of various cancers, including refractory solid tumours, ovarian cancer, triple-negative breast cancer, small cell lung cancer, and advanced or locally advanced solid tumours. It is in Phase 1 clinical development and is not yet approved.
AZD 1775 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The drug is currently in Phase 1 clinical trials for oncology indications.
AZD 1775 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety, tolerability, and pharmacokinetics in patients with various solid tumours.
AZD 1775 has been studied in several Phase 1 trials, including NCT02341456 (combination with carboplatin and paclitaxel in Asian patients), NCT02511795 (combination with olaparib in refractory solid tumours), NCT02610075 (monotherapy dose-finding study), and NCT02617277 (combination with durvalumab). All trials listed are completed.
Yes, AZD 1775 and AZD1775 refer to the same drug. The name is sometimes written with or without a space, but both forms denote the identical investigational compound being developed by AstraZeneca for oncology indications.
AZD 1775 is a small molecule that targets Wee1 kinase, a key regulator of the cell cycle checkpoint. By inhibiting Wee1, it disrupts DNA damage repair mechanisms in cancer cells, potentially enhancing the effects of chemotherapy or other anticancer agents.